Product Images Divalproex Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Divalproex Sodium NDC 70518-3055 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Divalproex Sodium 250mg 70518 3055 01
Divalproex Sodium is a medication that comes in a tablet form and has a strength of 250 mg. The medication is manufactured by Rising Pharma, Inc. located in Allendale, NJ 0740. The National Drug Code (NDC) for this medication is 70518-3055-01. The medication is in a delayed-release form, and the source NDC is 57237-0047-01. The medication should be kept out of reach of children, and the instructions for use can be found in the package insert. It is recommended to store the medication at a temperature between 20-26°C (63-77°F), and excursions are permitted at 15-30°C (59-86°F) [as per regulations defined in USP]. However, the text seems to have some non-ASCII characters and appears to be a bit distorted.*
Divalproex Sodium 250mg 70518 3055 02
Divalproex Sodium Delayed-Release is a medication that is produced by Rising Pharma, Inc., based in Allendale, NJ 07401. The medication is stored at a temperature of 20-26°C (63-77°F), with excursions permitted up to 15-30°C (59-86°F) as per USP regulations. It is repackaged by RemedyRepack Inc., based in Indiana, PA 15701, and the package insert should be consulted for the directions for use. The medication should be kept out of reach of children. The expiration date and lot number are not available in the text.*
Remedy_Label - Remedy Label
This is a medication called Divalproex Sodium with dosage strength of 250mg. The NDC number for this medication is 70518-3055-00 and it is manufactured by Rising Pharma Inc, Allendale, NJ. The lot number and expiry details are missing. The medication should be kept out of reach of children and should be stored at a temperature of 20-26°C (63-77°F) with excursions allowed to 15-30°C (59-86°F). The package insert should be consulted for directions on use.*
Figure 1 - divalproex fig1
Figure 2 - divalproex fig2
Figure 3 - divalproex fig3
This appears to be a graph displaying the reduction in CPS (unknown terminology) rate for high dose and low dose groups. The x-axis shows a percentage of patients while the y-axis shows percentage improvement, no change, and worsening. There is no further context provided.*
Figure 4 - divalproex fig4
This is a figure showing the mean 4-week migraine rates for two studies (Study 1 and Study 2) comparing a placebo to a medication called divalproex sodium in delayed-release tablets. The mean dose of divalproex sodium delayed-release tablets in Study 1 was 1,087 mg/day, while in Study 2 the dose was either 500 or 1,000 mg/day.*
Chemical Structure - divalproex str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.